ArticleAmerican journal of translational research2021
dNLR and TILS can be used as indicators for prognosis and efficacy evaluation of neo-adjuvant chemotherapy in breast cancer.
Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prognostic Value of Systemic Inflammatory Markers in Predicting Peritoneal Metastasis in Gastric and Gastroesophageal Junction Cancer.Clinical and translational science · 2026Observational
- Association between radiomics features of DCE-MRI and CD8Pathology oncology research : POR · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo explore the clinical value of dNLR and TILS in the prognostic diagnosis of breast cancer (BC) and the efficacy evaluation of neo-adjuvant chemotherapy.
methodsFrom January 2012 to January 2014, 72 patients with BC who received neo-adjuvant chemotherapy in our hospital were selected for this study and analyzed retrospectively. The clinical value of dNLR and TILS in the prognosis of BC was observed, and the clinical data of the patients were collected for Cox regression analysis to observe their independent prognostic indicators. According to the clinical efficacy of neo-adjuvant chemotherapy, patients were divided into effective group (EG) (CR+PR) and invalid group (IG) (SD+PD), and the value of dNLR and TILS in the therapeutic effect of patients was observed.
resultsAfter therapy, there were 10 cases of CR, 44 cases of PR, 13 cases of SD and 5 cases of PD in 72 patients. With the improvement of curative effect, the expression of dNLR was gradually declined (P < 0.05). The less effective the patients were, the less TILS positive rate was (P < 0.05). However, the expression of dNLR in the EG was obviously lower than that in the IG (P < 0.05). The area under dNLR curve was 0.844, while the area under TILS curve was 0.618. Multivariate Cox regression analysis revealed that TNM staging, dNLR and TILS were independent prognostic factors that affected the patients.
conclusionPatients with high expression of dNLR and TILS-negative BC have poor efficacy of neoadjuvant chemotherapy, and dNLR and TILS can be used as prognostic observation indexes for BC.
Indexed as
Identifiers
34956528PMC8661182What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.